|
|
atazanavir/ritonavir* |
↓ telaprevir
↑ atazanavir |
Concomitant administration of telaprevir and atazanavir/ritonavir resulted in reduced steady-state telaprevir exposure, while steady-state atazanavir exposure was increased. |
|
darunavir/ritonavir* |
↓ telaprevir
↓darunavir |
Concomitant administration of telaprevir and darunavir/ritonavir resulted in reduced steady-state exposures to telaprevir and darunavir. It is not recommended to co-administer darunavir/ritonavir and telaprevir. |
|
fosamprenavir/ritonavir* |
↓ telaprevir
↓fosamprenavir |
Concomitant administration of telaprevir and fosamprenavir/ritonavir resulted in reduced steady-state exposures to telaprevir and amprenavir. It is not recommended to co-administer fosamprenavir/ritonavir and telaprevir. |
|
lopinavir/ritonavir* |
↓ telaprevir
↔ lopinavir |
Concomitant administration of telaprevir and lopinavir/ritonavir resulted in reduced steady-state telaprevir exposure, while the steady-state exposure to lopinavir was not affected. It is not recommended to co-administer lopinavir/ritonavir and telaprevir. |
|
HIV-ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS |
|
efavirenz* |
↓ telaprevir
↓ efavirenz |
Concomitant administration of telaprevir and efavirenz resulted in reduced steady-state exposures to telaprevir and efavirenz. |
|
tenofovir disoproxil fumarate* |
↔ telaprevir
↑ tenofovir |
Concomitant administration of telaprevir and tenofovir disoproxil fumarate resulted in increased tenofovir exposure. Increased clinical and laboratory monitoring are warranted. Tenofovir disoproxil fumarate should be discontinued in patients who develop tenofovir-associated toxicities. |
|
HORMONAL CONTRACEPTIVES/ESTROGEN |
ethinyl estradiol*
norethindrone |
↓ ethinyl estradiol
↔ norethindrone |
Exposure to ethinyl estradiol was decreased when co-administered with telaprevir. Two effective non-hormonal methods of contraception should be used during treatment with telaprevir.
Patients using estrogens as hormone replacement therapy should be clinically monitored for signs of estrogen deficiency. Refer also to Contraindications (4), Warnings and Precautions (5.1), Use in Specific Populations (8.1), and Patient Counseling Information (17.1). |
|
IMMUNOSUPPRESSANTS |
cyclosporine*
sirolimus
tacrolimus* |
↑ cyclosporine
↑ sirolimus
↑ tacrolimus |
Plasma concentrations of cyclosporine and tacrolimus are markedly increased when co-administered with telaprevir. Plasma concentration of sirolimus may be increased when co-administered with telaprevir, though this has not been studied. Significant dose reductions and prolongation of the dosing interval of the immunosuppre |
